AQR Capital Management LLC Makes New $197,000 Investment in Fresenius Medical Care AG (NYSE:FMS)

AQR Capital Management LLC bought a new position in Fresenius Medical Care AG (NYSE:FMS) in the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund bought 10,340 shares of the company’s stock, valued at approximately $197,000.

Several other hedge funds and other institutional investors have also recently bought and sold shares of the company. Marshall Wace LLP grew its stake in Fresenius Medical Care by 8.5% in the 2nd quarter. Marshall Wace LLP now owns 15,363 shares of the company’s stock worth $293,000 after acquiring an additional 1,207 shares during the period. XTX Topco Ltd grew its stake in shares of Fresenius Medical Care by 82.1% during the 2nd quarter. XTX Topco Ltd now owns 23,282 shares of the company’s stock valued at $444,000 after buying an additional 10,497 shares during the period. Vanguard Personalized Indexing Management LLC grew its stake in shares of Fresenius Medical Care by 17.8% during the 2nd quarter. Vanguard Personalized Indexing Management LLC now owns 28,680 shares of the company’s stock valued at $548,000 after buying an additional 4,340 shares during the period. Mercer Global Advisors Inc. ADV grew its stake in shares of Fresenius Medical Care by 4.5% during the 2nd quarter. Mercer Global Advisors Inc. ADV now owns 14,581 shares of the company’s stock valued at $278,000 after buying an additional 624 shares during the period. Finally, Wulff Hansen & CO. grew its stake in shares of Fresenius Medical Care by 1,809.0% during the 2nd quarter. Wulff Hansen & CO. now owns 343,429 shares of the company’s stock valued at $6,556,000 after buying an additional 325,439 shares during the period. 8.25% of the stock is owned by hedge funds and other institutional investors.

Fresenius Medical Care Stock Performance

NYSE:FMS opened at $20.49 on Friday. The company has a current ratio of 1.46, a quick ratio of 1.09 and a debt-to-equity ratio of 0.45. The firm has a market capitalization of $12.02 billion, a price-to-earnings ratio of 23.02, a PEG ratio of 1.06 and a beta of 0.91. The firm’s fifty day simple moving average is $20.00 and its 200 day simple moving average is $20.06. Fresenius Medical Care AG has a twelve month low of $16.37 and a twelve month high of $22.76.

Fresenius Medical Care (NYSE:FMS) last posted its earnings results on Tuesday, July 30th. The company reported $0.38 earnings per share for the quarter, meeting the consensus estimate of $0.38. The business had revenue of $5.13 billion for the quarter, compared to analyst estimates of $5.28 billion. Fresenius Medical Care had a net margin of 2.72% and a return on equity of 5.48%. As a group, equities research analysts expect that Fresenius Medical Care AG will post 1.52 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

FMS has been the subject of several research reports. StockNews.com initiated coverage on shares of Fresenius Medical Care in a research note on Tuesday, October 8th. They set a “strong-buy” rating for the company. Truist Financial boosted their price objective on shares of Fresenius Medical Care from $22.00 to $23.00 and gave the company a “hold” rating in a research note on Monday, October 7th. One investment analyst has rated the stock with a sell rating, two have issued a hold rating, one has assigned a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat, the company presently has an average rating of “Hold” and an average target price of $23.00.

Fresenius Medical Care Profile

Fresenius Medical Care AG provides dialysis and related services for individuals with renal diseases in Germany, North America, and internationally. The company offers dialysis treatment and related laboratory and diagnostic services through a network of outpatient dialysis clinics; materials, training, and patient support services comprising clinical monitoring, follow-up assistance, and arranging for delivery of the supplies to the patient's residence; and dialysis services under contract to hospitals in the United States for the hospitalized end-stage renal disease (ESRD) patients and for patients suffering from acute kidney failure.